Topical Hemocoagulase for wound healing
Phase 4
Recruiting
- Conditions
- Health Condition 1: C109- Malignant neoplasm of oropharynx,unspecified
- Registration Number
- CTRI/2020/11/029267
- Lead Sponsor
- Jugaat Pharma
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients undergoing surgery as the primary modality of treatment for head and neck tumor.
Patients undergoing neck dissection for the surgical management of head and neck tumor.
Exclusion Criteria
Patients with history of systemic disease, CVS disease, Asthma, Hypertension, Diabetes, Coagulopathy, Bleeding disorder, Vascular anomaly, Anticoagulant therapy, Hypersensitivity to hemocoagulase and other constituents of the formulation.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Scar thickness <br/ ><br>Scar Elasticity <br/ ><br>Patient Observer Scar Assessment Scale (POSAS)Timepoint: 7th day <br/ ><br>4th week
- Secondary Outcome Measures
Name Time Method Patient Observer Scar Assessment Scale (POSAS)Timepoint: 7th post operative day and 4th post operative week